PMS42 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM